Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Evaluation of Glutathione Metabolic Genes on Outcomes in Advanced Non-small Cell Lung Cancer Patients after Initial Treatment with Platinum-Based Chemotherapy An NCCTG-97-24-51 Based Study

Evaluation of Glutathione Metabolic Genes on Outcomes in Advanced Non-small Cell Lung Cancer... ORIGINAL ARTICLE Evaluation of Glutathione Metabolic Genes on Outcomes in Advanced Non-small Cell Lung Cancer Patients after Initial Treatment with Platinum-Based Chemotherapy An NCCTG-97-24-51 Based Study Ping Yang, MD, PhD,* Sumithra J. Mandrekar, PhD,* Shauna H. Hillman, MS,* Katie L. Allen Ziegler, BS,* Zhifu Sun, MD, MS,* Jason A. Wampfler, BS,* Julie M. Cunningham, PhD,* Jeff A. Sloan, PhD,* Alex A. Adjei, MD, PhD,*† Edith Perez, MD,* and James R. Jett, MD* and measure the effects of these genes in chemotherapeutic regi- Introduction: We evaluated the role of glutathione-related geno- mens, drug toxicities, disease progression, and QOL are critical. types on overall survival, time to progression, adverse events, and Key Words: Gluthathione metabolic genes, Non small cell lung quality of life (QOL) in stage IIIB/IV non-small cell lung cancer cancer, Platinum-based chemotherapy. patients who were stable or responding from initial treatment with platinum-based chemotherapy and subsequently randomized to re- (J Thorac Oncol. 2009;4: 479–485) ceive daily oral carboxyaminoimidazole or a placebo. Methods: Of the 186 total patients, 113 had initial treatment with platinum therapy and DNA samples of whom 46 also had QOL data. latinum-based compounds remain the most commonly These samples were analyzed using six polymorphic DNA markers http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Evaluation of Glutathione Metabolic Genes on Outcomes in Advanced Non-small Cell Lung Cancer Patients after Initial Treatment with Platinum-Based Chemotherapy An NCCTG-97-24-51 Based Study

Journal of Thoracic Oncology , Volume 4 (4) – Apr 1, 2009

Loading next page...
 
/lp/wolters-kluwer-health/evaluation-of-glutathione-metabolic-genes-on-outcomes-in-advanced-non-CrIyPjmbbf

References (24)

ISSN
1556-0864
DOI
10.1097/JTO.0b013e31819c7a2c
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Evaluation of Glutathione Metabolic Genes on Outcomes in Advanced Non-small Cell Lung Cancer Patients after Initial Treatment with Platinum-Based Chemotherapy An NCCTG-97-24-51 Based Study Ping Yang, MD, PhD,* Sumithra J. Mandrekar, PhD,* Shauna H. Hillman, MS,* Katie L. Allen Ziegler, BS,* Zhifu Sun, MD, MS,* Jason A. Wampfler, BS,* Julie M. Cunningham, PhD,* Jeff A. Sloan, PhD,* Alex A. Adjei, MD, PhD,*† Edith Perez, MD,* and James R. Jett, MD* and measure the effects of these genes in chemotherapeutic regi- Introduction: We evaluated the role of glutathione-related geno- mens, drug toxicities, disease progression, and QOL are critical. types on overall survival, time to progression, adverse events, and Key Words: Gluthathione metabolic genes, Non small cell lung quality of life (QOL) in stage IIIB/IV non-small cell lung cancer cancer, Platinum-based chemotherapy. patients who were stable or responding from initial treatment with platinum-based chemotherapy and subsequently randomized to re- (J Thorac Oncol. 2009;4: 479–485) ceive daily oral carboxyaminoimidazole or a placebo. Methods: Of the 186 total patients, 113 had initial treatment with platinum therapy and DNA samples of whom 46 also had QOL data. latinum-based compounds remain the most commonly These samples were analyzed using six polymorphic DNA markers

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Apr 1, 2009

There are no references for this article.